IgG Antibodies to GlcNAc<i>β</i> and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment

<div>ROC curve analysis of the pretreatment level of anti-GA2 IgG in patients with the response to antiviral treatment: specificity of 0.70; sensitivity of 0.62.</div>

Disease Markers

fig4

Figure 4

Figure 4: IgG Antibodies to GlcNAc<i>β</i> and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment 

Figure 4 | IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment 